CervoMed SEC Filings

CervoMed Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is attached to the Form 8-K as Exhibit 99.1 and is incorporated by reference into Item 2.02, and the filing states that the information is being furnished under Item 2.02 rather than filed for purposes of Section 18 of the Exchange Act. Item 9.01 lists Exhibits 99.1 (the press release) and 104 (cover page interactive data file).

CervoMed (CRVO) 10-Q, Q2-25: The neuro-focused biotech remains pre-commercial and relies on NIA grant income. Q2 grant revenue fell 46% YoY to $1.76 million as RewinD-LB funding winds down, while R&D expense rose 35% to $5.1 million and G&A climbed 30% to $3.3 million. Operating loss therefore more than doubled to $6.6 million; net loss was $6.3 million (-$0.70/sh) versus $2.3 million (-$0.27/sh) a year earlier. For the six-month period, revenue dropped 35% to $3.7 million and net loss widened to $11.2 million.

Cash & cash equivalents were $8.3 million and marketable securities $25.2 million, giving $33.5 million of liquid resources versus $38.9 million at year-end. Operating cash burn reached $10.4 million YTD, partially offset by $4.6 million raised via a May 2025 at-the-market sale of 550k shares. Management believes current funds plus remaining $2.9 million of NIA grant receivables support operations for “at least” 12 months but acknowledges the need for additional capital to advance lead asset neflamapimod beyond ongoing Phase 2 programs. Shares outstanding rose to 9.25 million.

CervoMed (NASDAQ:CRVO) filed an 8-K (Item 5.07) reporting voting results from its June 23 2025 Annual Meeting.

With 64.5% of shares represented, stockholders approved all four proposals: (1) election of seven directors; (2) ratification of RSM US LLP as 2025 auditor (5,571,505 for, 25,008 against); (3) advisory endorsement of 2024 executive pay (3,891,229 for, 33,195 against); and (4) adoption of the 2025 Equity Incentive Plan (3,798,568 for, 137,758 against). No other material changes, governance shifts, or financial impacts were disclosed.

Insider filing overview: CervoMed Inc. (CRVO) submitted a Form 4 reporting an equity award to newly elected director Frank Zavrl.

• Transaction date: 23 June 2025, reported on 25 June 2025.
• Instrument: Non-qualified stock option covering 8,100 shares of CervoMed common stock.
• Exercise price: $6.52 per share.
• Term: Option expires 23 June 2035 (10-year life).
• Vesting schedule: 1/12th of the option (≈675 shares) vests monthly on the last calendar day from 30 June 2025 through 31 May 2026, contingent on continued board service.
• Ownership impact: Following the grant, Zavrl beneficially owns 8,100 derivative securities; no open-market purchases or sales of common shares were reported.

The award was made under CervoMed’s 2025 Equity Incentive Plan in accordance with the company’s non-employee director compensation policy. No 10b5-1 trading plan was indicated, and no changes were disclosed to Zavrl’s direct or indirect ownership of non-derivative shares.

Investor takeaways: The filing represents routine onboarding compensation, aligning a new board member’s interests with shareholders. Dilution effect is immaterial at less than 0.1 % of the company’s outstanding shares (exact share count not provided in the filing). No immediate cash outflow or revenue impact arises, and the option strike price embeds future performance risk.

On 25-Jun-2025 CervoMed Inc. (CRVO) filed a Form 4 reporting that director and 10% owner Joshua S. Boger received a stock-option award on 23-Jun-2025. The grant covers 8,100 shares of common stock, exercisable at $6.52 per share under the 2025 Equity Incentive Plan. Vesting occurs in equal monthly 1/12th installments beginning 30-Jun-2025 and ending after one year, subject to Mr. Boger’s continued board service. No shares were bought or sold; the filing simply discloses a new derivative position. If exercised, the options would modestly increase the share count, but the size of the award is immaterial to the company’s overall capital structure. The transaction signals standard director compensation and better aligns the director’s economic interests with shareholders.

CervoMed Inc. (CRVO) Form 4 filing discloses an initial equity grant to newly elected non-employee director Dr. Marwan Sabbagh. On 06/23/2025 he received a stock option for 8,100 common shares at an exercise price of $6.52 under the 2025 Equity Incentive Plan. The option vests in equal 1/12-increments on the last day of each month from 06/30/2025 through 05/31/2026, contingent on continued board service, and expires on 06/23/2035. No common shares were purchased or sold, and total derivative holdings now stand at 8,100 options. The transaction is routine director compensation with negligible dilution and no immediate impact on CervoMed’s financial position.